Company Directory

AI genomics for drug target discovery

OutSee is a genomics and drug discovery company using proprietary AI technology to identify and validate novel therapeutic targets. Its core platform applies predictive algorithms to large-scale genomic datasets to uncover disease-modulating biological mechanisms, complementing traditional analysis methods. OutSee partners with organisations including Genomics England and FinnGen, and has entered a drug discovery collaboration with o2h discovery to progress its lead target candidate.

Genotyping reagents and assay solutions

3CR Bioscience is a UK-based life science company developing PCR-based genotyping reagents, assay kits and related instrumentation for molecular biology and genomics applications. The company provides SNP and indel genotyping chemistries, DNA extraction products and custom assay development services supporting agricultural, animal, microbial and life science research. 3CR Bioscience’s products and services are used by academic institutions, breeding programmes and commercial laboratories for genetic analysis and marker-assisted research.

Genomic risk prediction platform for preventive healthcare and drug discovery

Genomics is a data science company that uses large-scale human genetic data to power precision healthcare and drug discovery. Its proprietary platform links millions of genetic variants to thousands of biological measurements and disease outcomes, generating polygenic risk scores that enable earlier identification of individuals at risk of common diseases. The company works with NHS partners, pharmaceutical companies, and insurers, and has a particular focus on cardiovascular disease risk stratification.

3D multi-omics platform for genetically validated drug target discovery

Enhanced Genomics is a biotechnology company developing a proprietary 3D multi-omics platform that maps genome-wide chromatin interactions to identify genetically validated drug targets for common diseases. Using patented technology integrated with a human cell type-specific multi-omics atlas, the platform links non-coding disease-associated genetic variants to causal target genes in relevant cell types. Enhanced Genomics serves pharmaceutical and biotech partners and is building an internal therapeutics pipeline focused on autoimmune conditions.

Targeted transcriptomic sequencing services for diagnostics and drug discovery

BioClavis is a genomics R&D and services laboratory leveraging their targeted RNA sequencing platform for high-throughput transcriptomic and biomarker analysis. The platform enables customisable gene expression profiling from crude cell lysates and archival FFPE tissue without nucleic acid purification, making it suited to large-scale clinical and drug discovery studies. Services cover companion diagnostic development, drug and biomarker discovery, and toxicology profiling. BioClavis also develops proprietary precision diagnostic tests for clinical applications.

Genetic insights to guide drug discovery and development

Sequoia Genetics is a contract research organisation applying human genetic data to inform drug discovery and clinical development. The company works with pharmaceutical companies, biotechnology firms, investors, and academic institutions to generate and interpret genetic insights that can guide target validation and development decisions, improving the efficiency of the drug development process before clinical trials begin. The team spans genetics, epidemiology, statistics, and data science.

Inkjet microarray printing instruments and contract array services

Arrayjet is a manufacturer of inkjet-based microarray printing instruments and a provider of contract array research and manufacturing services. The company's patented non-contact dispensing platform prints proteins, antibodies, nucleic acids, and small molecules onto solid substrates for applications including antibody characterisation, biomarker discovery, genomic profiling, and multiplex diagnostic development. Services span assay development, array manufacture, and scale-up to commercial production.